India, May 22 -- French drug major Sanofi (SNY), announced that it has agreed to acquire Vigil Neuroscience, Inc. (VIGL), a clinical-stage biotechnology company that develops investigational Alzheimer's drug VG-3927.
The company will acquire Vigil for $8 per share in cash at closing, which represents an equity value of approximately $470 million.
Additionally, shareholders will get a $2 deferred payment per share via a non-transferable CVR, tied to the first commercial sale of VG-3927.
Vigil in a statement said that the total equity value of deal, including the potential CVR payment, represents around $600 million.
The transaction is expected to close in the third quarter of 2025.
However, VGL101, Vigil's second molecule program, is no...